良性甲状腺结节微波消融的临床结局与体积缩小预测因素:单发结节与多结节性甲状腺肿的比较研究
单中心回顾性评估112例良性甲状腺结节患者接受微波消融,比较单发结节与多结节性甲状腺肿的体积缩小率并评估自主功能性结节。12个月技术有效率为94.6%,两组体积缩小率无显著差异,钙化、结节成分和每毫升能量是体积缩小率的独立预测因素。
要点
- 微波消融后12个月技术有效率达94.6%,中位体积缩小率88.2%。
- 单发结节与多结节性甲状腺肿的12个月体积缩小率无显著差异(89.0% vs 87.5%,p=0.973)。
- 钙化、结节成分和每毫升能量是体积缩小率的独立预测因素(p均<0.001)。
核心结论
- 微波消融是良性甲状腺结节有效且安全的治疗,单发结节和多结节性甲状腺肿均显示高技术有效率和显著体积缩小;每毫升能量、结节成分和钙化是体积缩小率的独立预测因素;微波消融似乎是有前景的自主功能性甲状腺结节治疗选择。
研究设计与样本
- 单中心回顾性评估,纳入2023年6月至2024年6月期间接受微波消融的112例患者,术后3、6、12个月行常规超声和临床评估,技术有效定义为消融后初始结节体积缩小50%或以上,采用多元线性回归模型分析体积缩小率的影响因素。
关键影像表现/征象
- 112次消融中50次(44.6%)针对单发结节,62次(55.4%)针对多结节性甲状腺肿。
- 中位初始结节体积为10.66 mL。
- 中位体积缩小率3个月为62.9%、6个月为80.5%、12个月为88.2%。
- 单发结节与多结节性甲状腺肿各随访间隔体积缩小率均无显著差异,12个月为89.0% vs 87.5%(p=0.973)。
诊断标准与关键数值
- 技术有效定义为消融后初始结节体积缩小50%或以上,12个月时94.6%的结节达到技术有效。
- 多元分析显示钙化、结节成分和每毫升递送能量是体积缩小率的显著独立预测因素(p均<0.001)。
- 18例自主功能性甲状腺结节患者中11例治疗前需抗甲状腺药物,微波消融后7例(63.6%)成功停药并维持甲状腺功能正常(p<0.001)。
临床应用与阅片要点
- 术后3、6、12个月行常规超声评估体积缩小率,12个月中位体积缩小率88.2%、技术有效率94.6%。
- 单发结节与多结节性甲状腺肿的12个月体积缩小率无显著差异(89.0% vs 87.5%,p=0.973)。
- 钙化、结节成分和每毫升能量是体积缩小率的独立预测因素(p均<0.001),阅片评估结节特征时需关注钙化和成分。
- 无严重并发症,3例(2.7%)出现短暂声音嘶哑,无永久性损伤;美容评分显著改善(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To investigate the efficacy and safety of microwave ablation (MWA) for benign thyroid nodules, including a comparison of volume reduction rates (VRR) between solitary nodules and multinodular goiters (MNG), and an assessment of autonomously functioning thyroid nodules (AFTN).
MATERIALS AND METHODS: A single-center retrospective evaluation was conducted on 112 patients treated with MWA between June 2023 and June 2024. Routine ultrasound and clinical evaluations were performed at 3, 6, and 12 months postoperatively after the MWA procedure. Technical efficacy was defined as a 50% or more reduction in the initial nodule volume after ablation. Outcomes assessed included VRR, technical efficacy, complication rates, cosmetic scores, and therapeutic success for AFTN. A multiple linear regression model was employed to examine potential factors influencing the VRR.
RESULTS: The majority of patients were female (68.48%), with a mean age of 57.84±11.10years. The median initial nodule volume was 10.66 mL. Of the 112 ablations performed, 50 (44.6%) targeted solitary nodules and 62 (55.4%) MNGs. The median VRR was 62.9% at 3 months, 80.5% at 6 months, and 88.2% at 12 months. Technical efficacy was achieved in 94.6% of nodules at 12 months. No significant difference in VRR was found between solitary nodules and MNG at any follow-up interval (12-month VRR: 89.0% vs. 87.5%, p=0.973). Multivariate analysis identified the presence of calcification, nodule composition, and energy delivered per mL as significant independent predictors of the VRR (p<0.001 for all). Of the 18 patients with AFTNs, 11 required antithyroid medication before treatment. Following MWA, seven of these 11 patients (63.6%) successfully discontinued medication and maintained euthyroidism, a result that was statistically significant (p<0.001). There were no major complications. Transient hoarseness was observed in three patients three patients (2.7%), with no permanent deficits. Cosmetic scores showed significant improvement (p<0.001).
CONCLUSION: MWA is an effective and safe treatment for benign thyroid nodules, demonstrating high technical efficacy and significant volume reduction for both solitary nodules and MNG. Energy delivery per mL, nodule composition, and the presence of calcification were identified as significant independent predictors of the VRR. Furthermore, MWA shows promise as a viable treatment option for AFTNs.
引用
- Eryuruk U, Bekci̇ T, Tonkaz M, et al. Clinical Outcomes and Volume Reduction Predictors Following Microwave Ablation of Benign Thyroid Nodules: A Comparative Study of Solitary Nodules and Multinodular Goiters. Acad Radiol. 2025. PMID: 40987674. doi:10.1016/j.acra.2025.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。